Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
EAST RUTHERFORD, N.J., May 01, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2017 financial results will be released on Thursday, May 4, 2017 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2017 Earnings Conference Call | ||
| When: | Thursday, May 4, 2017 at 8:30 a.m. Eastern Time | |
| Dial-in: | 1-877-876-9177 for U.S. 1-785-424-1666 for International Passcode: 6087850 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. 1-719-457-0820 for International Passcode: 6087850 Available through Thursday, May 11, 2017 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201-804-3037 Email: [email protected]
